Presentation is loading. Please wait.

Presentation is loading. Please wait.

Plasma concentration of metabolite M1 (left panel), glucose infusion rate (GIR) to maintain euglycemia (middle panel), and blood glucose concentration.

Published byTove Knudsen Modified over 5 years ago

Similar presentations

Presentation on theme: "Plasma concentration of metabolite M1 (left panel), glucose infusion rate (GIR) to maintain euglycemia (middle panel), and blood glucose concentration."— Presentation transcript:

1 Plasma concentration of metabolite M1 (left panel), glucose infusion rate (GIR) to maintain euglycemia (middle panel), and blood glucose concentration (right panel) in the clamp studies after subcutaneous injection of 0.3, 0.6, and 1.2 units · kg−1 glargine (upper, middle, and lower panels) in subjects with type 1 diabetes. Plasma concentration of metabolite M1 (left panel), glucose infusion rate (GIR) to maintain euglycemia (middle panel), and blood glucose concentration (right panel) in the clamp studies after subcutaneous injection of 0.3, 0.6, and 1.2 units · kg−1 glargine (upper, middle, and lower panels) in subjects with type 1 diabetes. Medians (solid lines) and 25th–75th percentiles are given (dotted and dashed lines). LLOQ: 33 pmol · L−1 (solid line) for M1. Plasma glargine and M2 concentrations are not presented since its concentrations nearly always fall below LLOQ (see results). Geremia B. Bolli et al. Dia Care 2012;35: ©2012 by American Diabetes Association

Download ppt "Plasma concentration of metabolite M1 (left panel), glucose infusion rate (GIR) to maintain euglycemia (middle panel), and blood glucose concentration."

Similar presentations

New Insulin Glargine 300 Units∙mL2-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine.

New Insulin Glargine 300 Units∙mL2-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine.
Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.
From: Effect of a Low-Carbohydrate Diet on Appetite, Blood Glucose Levels, and Insulin Resistance in Obese Patients with Type 2 Diabetes Ann Intern Med.

From: Effect of a Low-Carbohydrate Diet on Appetite, Blood Glucose Levels, and Insulin Resistance in Obese Patients with Type 2 Diabetes Ann Intern Med.
Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.

Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.
Study design. Study design. Each subject with or without type 2 diabetes participated in euglycemic and hypoglycemic clamp visits separated by 4–8 weeks.

Study design. Study design. Each subject with or without type 2 diabetes participated in euglycemic and hypoglycemic clamp visits separated by 4–8 weeks.
Plasma active glucagon-like peptide-1 (GLP-1) response in patients with type  2 diabetes during the liquid high-fat meal test at baseline, 12 weeks and.

Plasma active glucagon-like peptide-1 (GLP-1) response in patients with type  2 diabetes during the liquid high-fat meal test at baseline, 12 weeks and.
Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.
Dose response of pAGA1 and pFIG1 induction

Dose response of pAGA1 and pFIG1 induction
Differences in the glycated hemoglobin (HbA1c) levels.

Differences in the glycated hemoglobin (HbA1c) levels.
The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.
Clarke Error Grids (ISO15197; 2013) of StatStrip and coincident FSLTab-CGM arm (upper left panel), FSL-CGM abdomen (lower left panel) and FSLC readings.

Clarke Error Grids (ISO15197; 2013) of StatStrip and coincident FSLTab-CGM arm (upper left panel), FSL-CGM abdomen (lower left panel) and FSLC readings.
Glycated hemoglobin (HbA1c) trajectories among children during the first 5 years after diagnosis of type 1 diabetes, stratified by diagnostic era and diagnostic.

Glycated hemoglobin (HbA1c) trajectories among children during the first 5 years after diagnosis of type 1 diabetes, stratified by diagnostic era and diagnostic.
Figure 3 Pharmacodynamic action profiles of long-acting insulins

Figure 3 Pharmacodynamic action profiles of long-acting insulins
Box plot representing the median GIRs (mg/kg/min) by CD300LG genotype during the last 30 min of the HEC. The center lines show the medians; box limits.

Box plot representing the median GIRs (mg/kg/min) by CD300LG genotype during the last 30 min of the HEC. The center lines show the medians; box limits.
Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.
Mathematical modeling of bubble formation in insulin pump cartridges (3 mL solid line, 2 mL dotted line, and 1.8 mL dashed line) and lines during an increase.

Mathematical modeling of bubble formation in insulin pump cartridges (3 mL solid line, 2 mL dotted line, and 1.8 mL dashed line) and lines during an increase.
Prevalence of microvascular and macrovascular complications compared between cohort 1 and cohort 2 for subjects with type 2 (A, upper panel) and type 1.

Prevalence of microvascular and macrovascular complications compared between cohort 1 and cohort 2 for subjects with type 2 (A, upper panel) and type 1.
Whole-body glucose kinetics in C and T2D-O during postabsorptive and clamp states. Whole-body glucose kinetics in C and T2D-O during postabsorptive and.

Whole-body glucose kinetics in C and T2D-O during postabsorptive and clamp states. Whole-body glucose kinetics in C and T2D-O during postabsorptive and.
Hyperinsulinemic-euglycemic clamps revealed that obese TPL2KO mice have an improved insulin sensitivity compared with obese WT mice. Hyperinsulinemic-euglycemic.

Hyperinsulinemic-euglycemic clamps revealed that obese TPL2KO mice have an improved insulin sensitivity compared with obese WT mice. Hyperinsulinemic-euglycemic.
The development of plasma (p-)C-peptide responses to an intravenous glucose (0.5 g glucose/kg body wt) and glucagon (1 mg) infusion test up to 5–7 years.

The development of plasma (p-)C-peptide responses to an intravenous glucose (0.5 g glucose/kg body wt) and glucagon (1 mg) infusion test up to 5–7 years.

Similar presentations

Ads by Google